Literature DB >> 2078333

Cellular abnormalities in common variable immunodeficiency.

G P Spickett1, A D Webster, J Farrant.   

Abstract

In most patients with common variable immunodeficiency (CVI) there is evidence for an intrinsic B cell defect, despite an apparently normal cell phenotype. There are at least five separate subgroups of CVI, based on B cell function. These groups may be variations in severity of a single defect, or distinct molecular defects. At least some patients may have an abnormality in the secretory process of the B cell. The existence of patients whose cells can secrete IgM and IgG in vitro and yet are hypogammaglobulinaemic in vivo implies that the architecture of lymphoid organs or the traffic of lymphoid cells may be involved in the pathogenesis of the disease. The data on T cell defects in CVI indicates that, with sensitive assays, many patients have some abnormality. In the face of a much more defined B cell defect it is not yet possible to assess the overall contribution of the T cell defects to the immune failure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2078333

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  26 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Changes in serum immunoglobulin patterns in adults with common variable immunodeficiency.

Authors:  M Seligmann; P Aucouturier; F Danon; J L Preud'Homme
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

3.  Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency.

Authors:  M E North; G P Spickett; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

4.  Granulomatous disease in common variable immunodeficiency: effect on immunoglobulin replacement therapy and response to steroids and splenectomy.

Authors:  G P Spickett; J G Zhang; T Green; J Shrimankar
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

5.  Long-term follow-up on affinity maturation and memory B-cell generation in patients with common variable immunodeficiency.

Authors:  V Ballegaard; H Permin; T L Katzenstein; H V Marquart; L Schejbel
Journal:  J Clin Immunol       Date:  2013-05-07       Impact factor: 8.317

6.  Adhesion molecules in common variable immunodeficiency (CVID)--a decrease in L-selectin-positive T lymphocytes.

Authors:  I Nordøy; F Müller; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  Effect of 12,13-phorbol dibutyrate and ionomycin on defective B cells in common variable immunodeficiency.

Authors:  A Franz; A Bryant; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

8.  B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis.

Authors:  A Saxon; B Keld; D Diaz-Sanchez; B C Guo; N Sidell
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

9.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency.

Authors:  Asghar Aghamohammadi; Hirokazu Kanegane; Mostafa Moein; Abolhasan Farhoudi; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Ali Akabar Amir Zargar; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.